No Data
Palatin Technologies Enters Warrant Inducement Agreement With Institutional Investor To Exercise 3,233,277 Shares Issued In November 2022 And October 2023, Raising $6.1M
Palatin Technologies Enters Warrant Inducement Agreement With Institutional Investor To Exercise 3,233,277 Shares Issued In November 2022 And October 2023, Raising $6.1M
Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds
Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based...
Express News | Palatin Technologies: Potential Phase 3 Clinical Study in Ed Patients Who Do Not Respond to Pde5I Monotherapy to Start in H1 2025
Express News | Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered With a Pde5I for the Treatment of Erectile Dysfunction (Ed)
Sector Update: Health Care Stocks Ease Late Afternoon
Health care stocks were softer late Wednesday afternoon, with the NYSE Health Care Index decreasing 0.3% and the Health Care Select Sector SPDR Fund (XLV) down 0.1%. The iShares Biotechnology ETF (IBB
Palatin Technologies Starts Phase 2 of Obesity Treatment Study
Palatin Technologies (PTN) said Wednesday it has started a phase 2 clinical trial to assess the safety and efficacy of bremelanotide, a melanocortin 4 receptor agonist, administered alongside tirzepat